Immunotherapy Patients Have Access To:

  • The Blood and Marrow Transplant Group of Georgia physician team. The physicians have completed post-hematology/oncology fellowship training in hematopoietic stem cell transplantation and have vast experience administrating immunotherapy agents for hematological malignancies.
  • Interdisciplinary Team that includes a dedicated health psychologist, social worker, clinical BMT Pharm D.’s, nutritional services, physical therapy, and chaplain services
  • State-of-the-Art facilities
  • Comprehensive quality management program
  • Leading-edge clinical research trials
  • The Blood and Marrow Transplant Program at Northside Hospital has among the BEST BMT survival outcomes in United States
    • Only BMT program in the country, and in Georgia, to achieve survival outcomes that significantly exceeded the expected survival rate for allogeneic and unrelated donor transplants for the last 12 consecutive reporting cycles (2009-2020).*
  • NH-BMT is one of twenty national BMT Programs and Program Consortia to be selected as a Core Clinical Center for the Blood and Marrow Transplant Clinical Trials Network (BMT CTN).
  • Program physicians will coordinate pre – post infusion care with your referring physician.
  • Leading-edge clinical research trials are available so patients can stay close to home for innovative treatment.
    • Program participates in large national cooperative group clinical research trials and collaborates with academic-university institutions and the pharmaceutical industry.
    • NCI- NCORP: Northside Hospital Cancer Institute and Lewis Cancer and Research Pavilion have collaborated with Georgia CORE to participate in NCORP. After a successful first five years, a statewide cancer research consortium has been awarded a six-year grant expected to result in more than $11 million in funding from the NCI to enroll even more Georgians in important clinical trials.

*For the twelfth consecutive year (2009-2020) NH-BMT achieved survival outcomes that significantly exceeded the expected range as reported in the Center for International Blood and Marrow Transplant Research Final 2019 Transplant Center Specific Survival Report, December 14, 2020 and from reported outcome data from Be The Match®. There were 172 adult and pediatric transplant centers included in the analysis. This survival information includes only patients who received their first allogeneic transplant between January 1, 2016 and December 31, 2018 using unrelated or related donors and who had reported follow-up. Specific transplant center information can be found at bethematch.org.